Eli Lilly's Zepbound gains market share against Novo Nordisk

Name: Eli Lilly's Zepbound gains market share against Novo Nordisk
Uploaded: 2026-02-23T20:56:21Z
Duration: 34 s
Description: Lauren Simonetti reports on Eli Lilly's new one-month dosage pen for Zepbound, its top-prescribed weight-loss drug, which is cheaper to manufacture. This development follows Novo Nordisk's experimental drug proving less effective, causing its stock to drop significantly.

Varney & Company · FBN · Feb 23, 2026 · 34sSign Up Now

Already a subscriber?

Lauren Simonetti reports on Eli Lilly's new one-month dosage pen for Zepbound, its top-prescribed weight-loss drug, which is cheaper to manufacture. This development follows Novo Nordisk's experimental drug proving less effective, causing its stock to drop significantly.